following a resubmission assessed under the end of life and orphan equivalent medicine process:
amivantamab (Rybrevant®) is accepted for use within NHSScotland.
Indication under review: in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.
In a phase III study of patients with locally advanced or metastatic NSCLC with EGFR Exon20 insertion mutations, the addition of amivantamab to carboplatin plus pemetrexed significantly improved progression-free survival.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- amivantamab (Rybrevant)
- SMC ID:
- SMC2878
- Indication:
In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 08 December 2025